Connor Clark & Lunn Investment Management Ltd. Has $2.36 Million Stock Position in Fulcrum Therapeutics, Inc. $FULC

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 57.3% during the second quarter, Holdings Channel.com reports. The firm owned 342,547 shares of the company’s stock after acquiring an additional 124,798 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Fulcrum Therapeutics were worth $2,357,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Jump Financial LLC bought a new stake in Fulcrum Therapeutics in the 1st quarter valued at about $30,000. Brooklyn Investment Group grew its stake in Fulcrum Therapeutics by 209.7% in the first quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock valued at $35,000 after acquiring an additional 8,254 shares during the period. Virtu Financial LLC bought a new stake in shares of Fulcrum Therapeutics during the first quarter valued at approximately $39,000. Vanguard Personalized Indexing Management LLC raised its position in shares of Fulcrum Therapeutics by 26.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock worth $89,000 after purchasing an additional 2,677 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Fulcrum Therapeutics in the 1st quarter worth $92,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Stock Down 1.6%

Shares of NASDAQ FULC opened at $8.65 on Friday. The company has a market capitalization of $468.14 million, a PE ratio of -7.33 and a beta of 3.02. The stock’s 50 day moving average price is $8.51 and its 200-day moving average price is $7.37. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $10.11.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). As a group, research analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on FULC. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 1st. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Fulcrum Therapeutics in a research report on Monday, October 20th. Leerink Partners set a $20.00 target price on shares of Fulcrum Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, October 21st. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price target (up previously from $12.50) on shares of Fulcrum Therapeutics in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.00.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.